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Abstract: A biomarker represents a tool possibly helping physicians in predicting onset, 
diagnosis, and progression of a disease as well as evaluating the response to disease-modifying 
treatments. Currently, there is no biomarker fulfilling all such ideal criteria for Parkinson’s 
disease (PD). In this article, we have critically reviewed the literature searching for the most 
reliable and reproducible clinical, biochemical, and imaging biomarkers for prodromal phase, 
diagnosis, and progression of PD. Different comprehensive batteries of biomarkers have been 
proposed as a sensitive approach to predict the onset of PD during the prodromal phase. 
There is a discussion about the redefinition of the clinical diagnosis of PD, including clinical 
biomarkers as non-motor symptoms; however, on the other hand, we have also observed that 
imaging biomarkers support the differential diagnosis from other causes of parkinsonism. 
Various clinical (eg, freezing of gait or cognitive impairment), biochemical (eg, epidermal 
growth factor, insulin-like growth factor 1, uric acid, etc), and imaging (eg, functional mag-
netic resonance imaging, voxel-based morphometry, etc) biomarkers may help envisaging 
disease progression of PD. To conclude, given the lack of a single biomarker that could track 
the entire course of the disease, our challenge is to find the best combinations of biomarkers 
for the different stages of the disease.
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Introduction
The National Institutes of Health defines a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a therapeutic intervention.”1 In 
the field of neurodegenerative diseases, a biomarker represents a tool possibly help-
ing physicians in predicting onset, diagnosis, and progression of a disease as well as 
evaluating the response to disease-modifying treatments (DMT).
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
after Alzheimer’s disease, affecting up to 1 million Americans over age 65 and up to 
10 million individuals worldwide.2 DMT as well as a cure for PD have yet to come. 
Current research is focusing on finding reliable biomarkers for PD which, ideally, 
should be sensitive, reproducible, inexpensive, noninvasive, and thoroughly validated. 
How can biomarkers really help us to tackle PD? The aim of this review is to find an 
answer to such a question by summarizing the current knowledge on clinical, imaging, 
and biochemical biomarkers for prodromal phase, diagnosis, and disease progression 
of PD (Tables 1–3).
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Table 1 Biomarkers for PD prodromal phase
Biomarker Comments References
Clinical biomarkers
Non-motor symptoms (NMS) Family history for either PD or tremor 4
Lack of smoking history 4,5
More frequent NMS 2 years before diagnosis: 3
anhedonia 3
apathy 3
memory complaints 3
inattention 3
More frequent NMS 2–10 years before diagnosis: 3
smell loss 3,10–12
mood disturbances 3
excessive sweating 3
fatigue 3
pain 3
other factors: tremor, balance impairments, constipation, hypotension, erectile  
dysfunction, urinary dysfunction, dizziness, fatigue, depression, and anxiety.
6–9
More frequent NMS more than 10 years before diagnosis: 3
constipation 3,9
dream-enacting behavior 3,10–12
frequent nightmares 3,10–12
excessive daytime sleepiness 3
postprandial fullness 3
other factor: tremor 9
Biochemical biomarkers
Metabolic factors Cholesterol may be either a protective or a risk factor for PD 14,15
Neurotrophic factors High iGF-1 16,17
Low vitamin D 18
Oxidative stress Protective role of higher uric acid levels and of gout in the development of PD 19–23
Imaging biomarkers
Nuclear imaging DaT imaging (DaTscan) is used to detect nigrostriatal degeneration; if combined with  
multiple factors (hyposmia, male sex, and constipation), the probability of detecting  
subjects with a nigrostriatal deficit increases up to 40%.
24–26
Transcranial sonography (TCS) Substantia nigra hyperechogenicity has been proposed as a prodromal biomarker  
of PD at both 3- and 5-year follow-up.
27,28
Sensitivity and specificity of PD conversion can be significantly increased when  
TCS is associated with nuclear imaging or applied in LRRK2 mutation carriers.
29–31
Magnetic resonance imaging (MRi) Functional MRi shows reorganization of corticostriatal circuits in LRRK2 mutation carriers 32
Note: DaTscan signifies dopamine transporter imaging technique.
Abbreviations: PD, Parkinson’s disease; iGF, insulin-like growth factor.
Methods
We searched the published data in English language from 
inception to November 2015 on PubMed. Our keywords 
included “Parkinson’s disease”, “biomarkers”, “imaging”, 
“clinical”, “serum”, “plasma”, and “cerebrospinal fluid or 
CSF”. Totally, we have retrieved 1,601 papers. Out of these, 
however, we considered only 141 papers for this review after 
excluding preclinical studies, reviews, duplicated data, and 
papers not specifically focused on PD.
Prodromal phase
Clinical biomarkers
Several retrospective studies have examined the frequency 
and timeline of clinical biomarkers prior to the onset of 
overt PD motor symptoms. In the ONSET PD (onset of non-
motor symptoms in PD) study, the occurrence of non-motor 
symptoms (NMS) prior to diagnosis was surveyed in 109 PD 
patients with an estimation of the time span between onset of 
NMS and motor symptoms (within 2 years; more than 2 but 
less than 10 years; and more than 10 years). The most com-
mon NMS reported to occur more frequently during the 2-year 
premotor period were anhedonia, apathy, memory complaints, 
and inattention. NMS occurring more frequently between 
2 and 10 years before motor onset were smell loss and mood 
disturbances, taste loss, excessive sweating, fatigue, and pain. 
NMS occurring usually more than 10 years before motor onset 
were constipation, dream-enacting behavior and frequent 
nightmares (both suggestive of rapid eye movement [REM] 
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Table 2 Biomarkers for PD diagnosis
Biomarkers Comments References
Clinical biomarkers
Non-motor symptoms (NMS) Frequent NMS at diagnosis: psychiatric disturbances, fatigue, attention/memory problems 34
Sleep symptoms (RBD and insomnia) associated with worse cognitive performances 35
Taste/smelling and difficulties in sexual activities more prevalent in men 36
Role of “red flags” in differential diagnosis with multiple system atrophy (MSA) 41
Biochemical biomarkers
Metabolic factors increased homocysteine and its metabolites (ie, methylmalonate or cystatin C) 42–44
Neurotrophic factors Low BDNF 46
High iGF-1 16,48,49
Low vitamin D 50,51
GH response to arginine test may be helpful in the differential diagnosis with MSA 47
Neuroinflammation PDGFB and prolactin are possible biomarkers for PD 52,53
Oxidative stress Bilirubin and ceruloplasmin have been variably associated with PD 54–57
Lower levels of uric acid in PD patients compared to healthy controls 58,59
iron and other metals iron and manganese have been variably associated with PD 62,63
α-Synuclein it is still debated if plasmatic levels of α-synuclein are similar or higher in PD, as compared  
to healthy controls; different methods to detect α-synuclein in plasma possibly account for  
such divergent results.
64–67
CSF biomarkers Altered Aβ peptides 68–70
Decreased α-synuclein 71,72
Higher tau protein 74
Higher DJ-1 75
Metabolomic studies 79,80
Imaging biomarkers
Nuclear imaging Evaluation of the presynaptic dopaminergic function by means of either 6-[18F] fluoro-l-dopa  
or vMAT 2 or DAT availability measurement can be helpful in differentiating degenerative  
parkinsonism from essential tremor and secondary parkinsonism, but it is not helpful in the  
differential diagnosis with atypical parkinsonism.
81,82
Cardiac [123i] metaiodobenzylguanidine (MiBG) scintigraphy may also be useful for the  
differential diagnosis with MSA.
83
DAT availability might be different between motor subtypes in relation to different disease  
severity; striatal dopamine depletion may also contribute to both cognitive (ie, executive tasks)  
and nonmotor symptoms (ie, anxiety) in de novo PD patients.
87–89
Magnetic resonance imaging  
(MRi)
Neuromelanin decrease (whose paramagnetic properties result in high signal on specific  
T1-weighted sequences) in the substantia nigra and locus coeruleus may differentiate  
between PD patients and healthy controls.
84
Functional MRi can discriminate among PD patients with TD and non-TD phenotype and  
healthy controls.
85
MRi shows positive correlation between TD phenotype and transverse relaxation rate  
(reflecting iron load) within the putamen, caudate, and thalamus.
86
Abbreviations: BDNF, brain-derived neurotrophic factor; IGF, insulin-like growth factor; CSF, cerebrospinal fluid; PD, Parkinson’s disease; PDGFB, platelet-derived growth 
factor subunit B; TD, tremor dominant; RBD, ReM-sleep behavior disorders; ReM, rapid eye movement; GH, growth hormone; Aβ, amyloid beta.
sleep behavior disorders, RBD), excessive daytime sleepiness, 
and postprandial fullness. Interestingly, constipation, frequent 
nightmares, and dream-enacting behavior were found to asso-
ciate together across all premotor time spans.3
A recent systematic meta-analysis showed that positive 
familial history for either PD or tremor, constipation, and 
lack of smoking history were strongly associated with later 
development of PD.4 In accordance with these data, a survey 
among 116 de novo PD patients and 232 controls showed 
that current smokers were less likely to have PD, while 
former smokers were more likely to have PD, as compared 
to never-smokers, further suggesting that quitting smoking 
may be considered an early NMS of PD.5
Further, in agreement with other data,6–8 a recent 
population-based study demonstrated that at 5 years before 
diagnosis, patients who went on to develop PD had a higher 
incidence of tremor, balance impairments, constipation, 
hypotension, erectile dysfunction, urinary dysfunction, 
dizziness, fatigue, depression, and anxiety compared with 
controls. At 10 years before diagnosis of PD, the incidence 
of tremor and constipation was higher in those who went on 
to develop PD than in controls.9 According to prospective 
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Table 3 Biomarkers for PD progression
Biomarker Comments References
Clinical biomarkers
Non-motor symptoms (NMS) NMS tend to remain stable during the early phase of disease. 97
Several clinical biomarkers herald worsening of cognition, as the presence of MCi, apathy,  
subjective memory complaints, and visual hallucinations.
98–103
Motor symptoms TD variant has a slower disease progression rate, less cognitive decline, and lower incidence  
of neuropsychiatric complications such as visual hallucinations and depression, when  
compared to the non-TD phenotype.
37,91
Freezing of gait may represent a biomarker for development of cognitive impairment and dementia. 93–96
Biochemical biomarkers
Metabolic factors The overall cardiovascular risk has been associated with axial motor impairment. 105
Neurotrophic factors Serum BDNF levels have been associated with the severity of PD motor symptoms  
and cognitive symptoms.
45,106
Serum epidermal growth factor (EGF) levels have been associated with cognitive deficits  
within 2 years since diagnosis.
107,108
iGF-1 levels have been associated with both motor and cognitive symptoms. 48,49
vitamin D levels were negatively associated with motor disability, cognitive functions,  
and psychiatric symptoms.
50,109
Oxidative stress Coenzyme Q10 levels are inversely associated with motor symptoms. 113
Higher bilirubin levels were associated with worse motor symptoms. 54
Higher UA levels were associated with less motor and non-motor burden. 114–123
iron and other metals Higher iron levels have been associated with the presence of RBD, poor quality of sleep,  
and depression.
125–127
Serum manganese and copper have been associated with depressive symptoms. 127
CSF biomarkers Conflicting results have been reported when analyzing the relationship between  
α-synuclein and motor severity of PD.
71,72,128,129
Higher phosphorylated-tau protein has been related with greater cognitive decline. 130,131
CSF Aβ peptides have also been studied in relation to cognitive functions in early PD,  
but conflicting results have been reported.
68,69
Imaging biomarkers
Magnetic resonance imaging  
(MRi)
Functional MRi shows resting-state functional connectivity changes in relation to cognitive decline 132,133
Gray matter volume analysis suggest that the caudate volume loss may contribute to cognitive  
decline while changes in thalamic volume may have relevance to tremor severity.
135
A positive correlation between Mini-Mental State examination scores and cortical thickness in  
the anterior temporal, dorsolateral prefrontal, posterior cingulate, temporal fusiform, and  
occipito-temporal cortex has been detected supporting the usefulness of cortical thickness  
measurement in assessing disease stage and cognitive impairment in patients with PD.
136,137
iron content in basal ganglia, assessed as MRi relaxation rate R2*, has been proposed as  
a biomarker of PD progression in PD.
138
Abbreviations: CSF, cerebrospinal fluid; IGF-1, insulin-like growth factor-1; PD, Parkinson’s disease; TD, tremor dominant; MCI, mild cognitive impairment; BDNF, brain-
derived neurotrophic factor; UA, uric acid; RBD, ReM-sleep behavior disorders; ReM, rapid eye movement; Aβ, amyloid beta, R2*, effective transverse relaxation rate.
studies, RBD and impaired olfaction are, by far, associated 
with the highest PD risk.10–12
The occurrence of NMS during the premotor phase 
reflects the widespread neurochemical and neuroana-
tomical changes that occur throughout the course of PD, 
with involvement of not only the dopaminergic nigros-
triatal system but also serotonergic and noradrenergic 
brain stem areas, cholinergic frontal and brain stem 
regions.13 However, each of these clinical biomarkers 
has poor predictive value when considered individually. 
Thus, ideally, screening strategies should include a com-
bination of clinical and imaging as well as biochemical 
biomarkers to increase the likelihood of diagnosing as 
many individuals (developing PD) as possible (see “Bio-
chemical biomarkers”).
Biochemical biomarkers
Metabolic factors
Conflicting data suggest that increase in total cholesterol 
may be either a protective or a risk factor for PD.14,15 Indeed, 
the association with motor symptoms may be explained in 
light of the white matter damage associated with metabolic 
factors, although a direct effect on neurodegenerative process 
has been hypothesized.
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Neurotrophic factors
Insulin-like growth factor 1 (IGF-1) has been shown to provide 
effective protection against the loss of dopaminergic neurons in 
cellular and animal models of PD. Preliminary studies found 
that IGF-1 levels were directly associated with the burden of 
motor dysfunction in subjects at risk of PD.16,17
Vitamin D may exert a neuroprotective activity, although 
the exact mechanism is not fully understood. Accordingly, 
a 30-year longitudinal Finnish study showed that individuals 
with higher serum vitamin D concentrations have a 30% 
reduced risk of PD.18
Neuroinflammation
Neuroinflammation indeed play a role in enhancing neurode-
generative processes. However, there are no studies on single 
markers of neuroinflammation.
Oxidative stress
Oxidative stress plays a significant role in PD pathogenesis. 
Uric acid (UA) has antioxidant and iron scavenger features, 
possibly providing natural neuroprotection against PD. Evi-
dence suggests a protective role of higher UA levels19–21and 
of gout in the development of PD.22,23
CSF biomarkers
To our knowledge, no study has investigated possible cere-
brospinal fluid (CSF) biomarkers for prodromal phase of 
PD to date.
imaging biomarkers
It is unrealistic to expect that a single biomarker will fulfill 
all the criteria for a reliable prodromal marker of PD. Indeed, 
using a combination of tools merging clinical and imaging 
biomarkers is the most likely rational approach. Different 
techniques have been used to visualize striatal or nigrostriatal 
denervation with nuclear imaging (both positron emission 
tomography [PET] and single-photon emission computed 
tomography [SPECT]) or the hyperechogenicity of the sub-
stantia nigra (SN) with transcranial sonography (TCS), while 
functional magnetic resonance imaging (fMRI) has been used 
to visualize abnormalities in corticostriatal circuits.
The Parkinson-Associated Risk Syndrome (PARS) study 
applied a two-stage screening strategy for PD consisting of 
olfactory testing followed by dopamine transporter (DaT) 
imaging (DaTscan) to detect nigrostriatal degeneration.24,25 
Among the 5,000 individuals screened with the 40-item Uni-
versity of Pennsylvania Smell Identification Test (UPSIT), 
669 were at or below the 15th percentile based on age and sex, 
indicating hyposmia.25 Among those, 303 (203 hyposmic and 
100 normosmic) were subjected to DaTscan, and nigrostriatal 
dysfunction was detected in 11% of the hyposmic subjects 
compared with 1% of the normosmic subjects. Combining 
multiple factors (hyposmia, male sex, and constipation) 
increased the probability of detecting subjects with a nigros-
triatal deficit, up to 40%.26
TCS is an imaging technique based on reflection and scat-
tering of ultrasound waves at interfaces with diverse acoustic 
impedance depicting the brain as the mesencephalon and the 
basal ganglia. The alteration in SN signal, seen as an area of 
increased signal intensity and extent (termed hyperechogenic-
ity), has been proposed as an easy and noninvasive biomarker 
of PD.27,28 The Prospective Validation of Risk factors for the 
development of Parkinson Syndromes (PRIPS) study showed 
that enlarged SN hyperechogenicity is a good biomarker of 
PD development at both 3-27 and 5-year follow-up.28 How-
ever, another prospective study showed low sensitivity and 
specificity of TCS in predicting conversion to PD in patients 
affected by idiopathic RBD when used alone.29 The Sleep 
Innsbruck Barcelona group showed that the combination of 
ioflupane (123I) single photon emission computed tomography 
([123I]-FP-CIT SPECT) and TCS can better predict conversion 
to synucleinopathy in idiopathic RBD.30
Healthy carriers of the G2019S LRRK2 mutation display 
a markedly increased, age-dependent risk of developing PD 
and, thus, represent an ideal enriched cohort to test the fea-
sibility of biomarkers’ screening approaches. Both TCS and 
fMRI show specific alterations in these individuals prior to 
PD diagnosis.31,32
Biomarkers for diagnosis
Clinical biomarkers
Currently, diagnosis of PD is based on the presence and 
combination of cardinal motor signs.33 However, increasing 
evidence suggests a major role for a complex spectrum of 
NMS in the characterization of PD since the onset, possibly 
helpful in the process of redefinition of PD diagnosis.12
The PRIAMO (PaRkInson And non-Motor symptOms) 
study first showed that early, drug-naïve patients complained 
more frequently about psychiatric disturbances (66%), fatigue 
(52%), and attention/memory problems (48%).34 Another 
study showed that both RBD and insomnia were associated 
with lower scores on several cognitive tests in early, drug-naïve 
patients possibly suggesting that sleep symptoms might be 
considered an early marker of dementia.35 A survey examining 
the prevalence of NMS at onset in 200 PD patients and 93 
healthy controls showed specific sex-related differences in the 
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spectrum of NMS with men with PD complaining of problems 
having sex and taste/smelling difficulties significantly more 
frequently than women with PD.36
From a purely motor perspective, it is possible to distin-
guish two main distinct clinical subtypes in consideration of 
the predominant motor features, a tremor dominant (TD) and 
an akinetic-rigid type (ART), and one mixed phenotype, not 
presenting one prevailing motor feature.37 In keeping with the 
increasing role of NMS, more recent approaches provide clas-
sification of PD patients at diagnosis based on both motor and 
non-motor features.38 A study performing a cluster analysis 
using data assessing both motor and NMS with a data-driven 
approach in 100 newly diagnosed untreated PD patients identi-
fied four distinct groups of patients, namely (1) benign pure 
motor, (2) benign mixed motor–non-motor, (3) non-motor 
dominant, and (4) motor dominant, suggesting the presence 
of a cross talk between motor and NMS in defining PD phe-
notype at diagnosis. As a matter of fact, the identification of 
such subtypes may have important implications for generating 
pathogenetic hypotheses and therapeutic strategies.39
Newer and even more recent approach for PD subtyping 
encompasses clinical and genetic data.40 A population-based 
modeling study proposed such a model which correctly 
distinguished PD patients from healthy controls in the 
Parkinson’s Progression Markers Initiative with high sensi-
tivity and specificity.40 Further application of this model to 
premotor prospective cohorts could facilitate identification 
of biomarkers and interventions.40
Another role for clinical biomarkers of diagnosis is 
to help differentiating PD from atypical parkinsonism, as 
multiple system atrophy (MSA). Besides the poor response 
to levodopa, and the additional presence of pyramidal or 
cerebellar signs or autonomic failure as major diagnostic 
criteria, certain other clinical features known as “red flags” or 
warning signs may raise the clinical suspicion of MSA.41
Biochemical biomarkers
Metabolic factors
Homocysteine is a neurotoxic, intermediary product of the 
methionine cycle, whose concentrations can be influenced 
by different factors and, in particular, by the genetic back-
ground.42 Interestingly, homocysteine and its metabolites (ie, 
methylmalonate or cystatin C) have been suggested to be 
increased in PD, since the time of the diagnosis.43,44
Neurotrophic factors
Preclinical evidence shows that the brain-derived neu-
rotrophic factor takes part in the survival and in the activity 
of striatal dopaminergic neurons. Accordingly, serum BDNF 
levels have been found to be decreased in PD patients as 
compared to controls45 and associated with striatal DaT 
binding.46
Growth hormone (GH) and growth hormone-inhibiting 
hormone (or somatostatin) pathways have been investigated 
as diagnostic markers of PD. In particular, the growth hor-
mone response to arginine test may be useful to differentiate 
PD from MSA.47
IGF-1 has been reported to be higher in PD patients than 
in controls16,48,49 with one single study suggesting that a cutoff 
value of 114 ng/mL might correctly differentiate de novo PD 
patients from controls.16
PD patients have lower serum vitamin D levels as com-
pared to controls.50 Given the fact that seasonal differences in 
vitamin D levels have been observed,50 one study suggested 
that the season of birth is a predictor of PD development.51
Neuroinflammation
Platelet-derived growth factor subunit B and prolactin 
as well as other neuroinflammatory markers have been 
reported as significantly different between PD patients and 
controls.52,53 However, conflicting results have been reported 
so far, possibly because of differences in methodologies 
applied for determining these markers and of heterogeneity 
in populations.
Oxidative stress
Bilirubin levels were reported to be either increased54 or 
decreased55 in PD patients compared to healthy controls. 
Overall, PD populations that have been described so far 
are heterogeneous, and these conflicting results might be 
explained by the presence of confounding factors affecting 
bilirubin levels and/or by bilirubin variations during the 
course of the disease.
Decreased serum ceruloplasmin levels might reflect 
more severe oxidative stress with subsequent neurodegen-
erative alterations. Accordingly, lower serum ceruloplasmin 
levels have been associated with younger age at onset of 
PD,56 and with more impaired neuroimaging features within 
the SN.57
Several meta-analyses confirm that PD patients, with 
particular regard to men, present lower UA levels as compared 
to controls, notwithstanding potential confounding factors 
(ie, body mass index or comorbidities).58,59 Interestingly, 
higher UA levels were associated with the likelihood of 
having a scan without evidence of dopaminergic deficit in 
a secondary analysis of the PRECEPT study (recruiting 
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800 early PD),60 and with an increased DaT availability 
among newly diagnosed PD patients, suggesting that neuro-
degenerative alterations can be tracked based on UA levels 
right from the early phases of the disease.61
iron and other metals
Each positive variation of 10 µg/dL of serum iron has been 
associated with 3%–10% reduced relative risk of having 
PD,62 suggesting the involvement of iron metabolism in PD 
pathogenesis.62 Among other metals, manganese (Mn) has 
been associated with PD.63
α-Synuclein
Lewy bodies, the neuropathological hallmark of PD, are 
mainly composed of α-synuclein (α-syn), and, thus, different 
studies have investigated α-syn as a diagnostic biomarker in 
serum and plasma.64,65 It is still debated if plasmatic levels of 
α-syn are similar,66 or higher in PD, as compared to healthy 
controls, when there is an increased efflux of the protein to the 
peripheral blood of these patients.67 However, utilization of 
different methods to detect α-syn in plasma possibly account 
for such divergent results.
CSF biomarkers
CSF amyloid beta peptides are altered from the early phases 
of PD,68,69 especially in patients with dementia.70 Regarding 
α-syn, the majority of recent studies have shown decreased 
CSF levels in PD patients, as compared to controls, although 
this marker apparently cannot distinguish among different 
synucleopathies.71–73 In addition, levels of CSF tau protein 
were higher in PD patients, in particular in the early phases, 
as compared to controls.74
Among other CSF biomarkers, DJ-1 levels were found 
to increase in early PD patients compared to controls.75 
However, CSF DJ-1 increased levels are not specific and, for 
instance, they are also raised in MSA.76 Furthermore, several 
studies suggest an increase in the number of CSF biomarkers 
with regard to the status of oxidative balance in PD patients 
when compared to controls.77,78
Different studies have been investigating difference 
in CSF metabolomics between PD patients and controls. 
In particular, metabolomics focuses on the quantitative 
analysis of the small metabolites affected by PD. Prelimi-
nary data show that specific combinations of metabolites 
can differentiate PD patients from healthy controls.79,80 
Overall, these studies provide a significant contribution 
in the identification of novel biomarkers that enable early 
diagnosis of the disease, as well as provide knowledge 
about the metabolic pathways and molecular mechanisms 
involved.
imaging biomarkers
Clinically, there is no indication to perform imaging stud-
ies when the patient fulfills PD clinical criteria33 and there 
is no diagnostic doubt. On the other hand, imaging may be 
sometimes helpful in the differential diagnosis with other 
movement disorders (ie, essential tremor and atypical par-
kinsonism). However, when it comes to research, imaging 
biomarkers may be helpful in further delineating the different 
PD phenotypes at diagnosis.
Evaluation of the presynaptic dopaminergic function by 
means of either 6-[18F] fluoro-l-dopa or VMAT 2 or DaT 
availability measurement can be helpful in differentiating 
degenerative parkinsonism from essential tremor (eg, DaT 
availability is approved by the Food and Drug Administration 
for this purpose),81 and secondary parkinsonism, but it is not 
helpful in the differential diagnosis with atypical parkin-
sonism. For this purpose, it may be useful to combine pre- and 
postsynaptic dopaminergic imaging (with PET tracers for 
D2-like dopamine receptors), or to use fluorodeoxyglucose-
PET which may disclose specific metabolic patterns for the 
different forms of atypical parkinsonism.82
As sympathetic denervation in PD involves postgangli-
onic neurons, and MSA affects the preganglionic neurons, 
cardiac [123I] metaiodobenzylguanidine scintigraphy may also 
be useful for the differential diagnosis of these disorders.83
Recent studies have suggested that neuromelanin decrease 
(whose paramagnetic properties result in high signal on 
specific T1-weighted magnetic resonance imaging [MRI]) in 
the SN and locus coeruleus of PD patients may differentiate 
between PD patients and healthy controls with high sensitiv-
ity and specificity.84
For a research purpose, imaging studies may further 
contribute in the delineation of different PD phenotypes 
at diagnosis. A recent fMRI study demonstrated that the 
subtype-specific functional networks could discriminate 
among PD patients with TD and non-TD phenotypes and 
healthy controls.85 Further supporting different imaging 
features according to motor phenotype, another MRI study 
detecting iron load found a positive correlation between TD 
phenotype and transverse relaxation rate (reflecting iron load) 
within the putamen, caudate, and thalamus.86
Nuclear imaging studies also suggest different patterns 
of uptake of radiotracers according to motor phenotype. 
A recent study investigating the role of presynaptic nigrostri-
atal dopaminergic damage in 51 drug-naïve PD patients with 
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ART and TD phenotypes found that ART patients presented 
higher motor scores and lower DaT availability in affected 
and unaffected putamen, suggesting that DaT availability 
might be different between motor subtypes in relation to 
different regimens of disease severity.87
Nuclear tracers may also present different patterns in 
relation to cognitive profile and NMS at PD diagnosis. 
Recent data suggest that striatal dopamine depletion may 
contribute to both cognitive (ie, executive tasks)88 and NMS 
(ie, anxiety)89 in de novo PD patients.
Biomarkers of progression
Clinical biomarkers
Identifying those patients at risk of greater progression (eg, 
with development of cognitive impairment) is of particular 
importance in order to include patients in clinical trials when 
DMT are available.
Based on pathological evidence,90 clinical studies showed 
that the TD variant has a slower disease progression, less 
cognitive decline, and lower incidence of neuropsychiatric 
complications such as visual hallucinations and depression, 
when compared to the ART group.37,91
Although dopaminergic treatment may mask disease 
progression, reported evidence suggests that several symp-
toms become severe with disease duration. However, little 
is known about the anatomical progression over the body 
segments of extrapyramidal signs in PD. Furthermore, a 
significant unmet need is the availability of instruments to 
detect disease progression, even in the early phase and on 
dopaminergic medications.92
Motor symptoms, as freezing of gait, may represent as 
a biomarker of development of cognitive impairment and 
dementia.93,94 Indeed, gait is not merely considered a pure 
motor task as evidence shows the influence of specific cogni-
tive profiles on gait parameters suggesting the existence of a 
complex interplay between gait and cognition.95,96
NMS generally tend to remain stable during the early 
phase of disease, with only a few of them being affected 
by dopaminergic therapy and, specifically, by the use of 
dopamine agonists (ie, reduction in depression and increase 
in weight).97,98 However, several clinical biomarkers have 
shown to herald worsening of cognition in PD patients, as the 
presence of mild cognitive impairment,99,100 apathy,101 sub-
jective memory complaints,102 and visual hallucinations.103 
Interestingly, a recent study suggested that voluptuary hab-
its might also affect the burden of NMS and, for instance, 
smoking might be associated with sleep disturbances and 
sexual difficulties.104
Biochemical biomarkers
Metabolic factors
The overall cardiovascular risk has been associated with the 
rate of accrual of axial motor impairment,105 possibly by 
determining white matter changes.
Neurotrophic factors
Brain-derived neurotrophic factor serum levels were found 
to be associated with the severity of PD motor symptoms 
and cognitive symptoms.45,106 Overall, these findings sug-
gest that brain-derived neurotrophic factor serum levels 
may represent a biomarker not only of motor and cognitive 
dysfunction in PD but also of the effects of treatments on 
these outcomes.
Epidermal growth factor acts as a neurotrophic factor on 
dopaminergic nigrostriatal neurons in animal models of PD. 
Confirming previous data,107 Pellecchia et al108 showed the 
association between levels of epidermal growth factor, measured 
at the time of PD diagnosis and cognitive deficits within 2-year 
follow-up, with particular regard to executive dysfunctions.
Intriguingly, Picillo et al48 suggested that IGF-1 levels 
might be associated with those motor symptoms predomi-
nantly responsive to dopaminergic treatment, as compared to 
the whole UPDRS-III score, since IGF-1 seems to act spe-
cifically on dopaminergic cells. With regard to NMS, IGF-1 
levels were positively associated with cognitive functions and, 
in particular, with executive and memory tasks.49
Vitamin D levels were negatively associated with 
motor disability,50,109 with cognitive functions (in particular 
with executive and memory tasks), and with psychiatric 
symptoms.
Neuroinflammation
Several neuroinflammatory factors were associated with 
motor and NMS in PD.110–112 However, these results are 
based on small samples and need to be replicated in different 
population in order to test their reliability.
Oxidative stress
Coenzyme Q10 is a powerful antioxidant whose levels are 
inversely associated with motor symptoms of PD, thus sup-
porting its therapeutic use.113
Higher bilirubin levels were associated with worse motor 
symptoms at the time of PD diagnosis in a cohort of 75 de 
novo patients, but with better ones after 2-year follow-up, 
suggesting that higher bilirubin levels might depict a more 
pronounced neurodegenerative process, but are possibly 
related to improved outcomes over time.54
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Higher UA levels were associated with slower motor 
progression and with a reduced risk of requiring levodopa 
treatment, in a secondary analysis of the DATATOP study.114 
The latter result has been confirmed in different studies 
conducted on de novo or advanced PD populations.115–117 It 
is worth noting that UA levels might be particularly lower in 
those subjects with predominant axial features, as compared 
to TD patients, suggesting a more severe disease course.118 
Accordingly, higher UA levels have been associated with 
80% reduced likelihood of wearing-off119 and with lower 
total score of the NMS questionnaire. In detail, UA levels 
have been associated with specific NMS, such as attention/
memory, depression/anxiety, and cardiovascular.117,120,121 
The association with the impairment of attention/memory 
domains seems particularly promising since confirmed by 
different studies exploring cognitive function with com-
prehensive neuropsychological batteries.122,123 Furthermore, 
a recent Phase 2 trial on the use of inosine in PD, a precur-
sor of UA, showed a possible association between increased 
UA levels and mood disorders assessed with the Geriatric 
Depression Scale.124
iron and other metals
Iron metabolism has been associated with the presence of 
RBD and, more in general, with poor quality of sleep in PD 
patients.125,126 Furthermore, there is preliminary evidence of 
higher iron levels in PD patients with depression.127
Manganese and copper have also been associated with 
depressive symptoms of PD, but these findings need to be 
confirmed by further studies on larger samples.127
CSF biomarkers
Conflicting results have been reported when analyzing the 
possible relationship between α-syn and motor severity of 
PD.71,128,129 In a secondary analysis of the DATATOP study, 
lower baseline CSF α-syn levels predicted a better pres-
ervation of cognitive functions in early PD patients after 
8-year-follow-up.72
Another analysis of the DATATOP study found an 
association between higher phosphorylated-tau protein 
and greater decline in cognitive functions but slower motor 
progression.130,131 Thus, it is clear that the role of tau protein is 
largely unknown, and, so far there are only association stud-
ies, not providing possible explanations on the importance 
of tau species in PD pathogenesis.
CSF amyloid beta peptides have also been studied in 
relation to cognitive functions in early PD, but conflicting 
results have been reported.68,69
imaging biomarkers
Once the overt disease has become manifested, imaging 
biomarkers of prodromal or diagnosis of PD (ie, TCS, DaT 
imaging, etc) do not reliably feature clinical disease pro-
gression and, thus, are not considered useful biomarkers of 
progression. Thus, other imaging markers are currently being 
tested and validated as biomarkers of disease progression and 
many other in this regard are in the pipeline.
A study evaluating fMRI whole-brain resting-state func-
tional connectivity changes in relation to cognitive decline 
found a decrease in functional connectivity in PD patients 
independent of aging effects and directly related to cognitive 
decline.132 These findings confirm previous data,133 and sup-
port the role of reduced functional connectivity in cognitive 
decline and dementia of PD.132
Previous evidence showed a resting state functional con-
nectivity disruption of “executive attention” and visual neural 
networks in association with the presence of freezing of gait 
in PD.134 Indeed, this data further strengthened the relation-
ship between gait and cognition in PD.134
PD pathology leads to volumetric changes in the brain. 
A study investigated the pattern of gray matter changes 
according to disease progression in 89 patients with PD and 
detected decreased gray matter volume in the fronto-temporo-
parietal areas and the bilateral caudate and increased gray 
matter volume in the bilateral limbic/paralimbic areas, medial 
globus pallidus/putamen, and the right occipital cortex as 
compared with healthy controls. This study suggested that 
the caudate volume loss may contribute to cognitive decline, 
while changes in thalamic volume may have relevance to 
tremor severity.135
Supporting previous findings,136 a recent study found a 
positive correlation between Mini-Mental State Examination 
scores and cortical thickness in the anterior temporal, dor-
solateral prefrontal, posterior cingulate, temporal fusiform, 
and occipito-temporal cortex, thus supporting the usefulness 
of cortical thickness measurement in assessing disease stage 
and cognitive impairment in patients with PD.137
Even more recently, changes in iron content in basal gan-
glia, assessed as MRI relaxation rate R2*, have been proposed 
as a biomarker of disease progression in PD, suggesting that 
R2* MRI could be an interesting tool for individual assess-
ment of neurodegeneration, and also be useful in testing the 
efficiency of DMT.138
Conclusion
In this review, we have summarized the current insights on 
clinical, imaging, and biochemical biomarkers as markers 
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for prodromal phase, diagnosis, and disease progression 
of PD. Indeed, it is unrealistic to expect that there will be 
a unique biomarker useful to discriminate between PD and 
other diseases with high sensitivity and specificity as well as 
to track progression throughout the entire disease course.139 
By combining microscopic (CSF α-syn) and macroscopic 
(fMRI functional connectivity) observations, as well as 
Pittsburgh compound B-PET imaging to detect amyloid 
beta peptides’ deposit, Campbell et al140 provided a first step 
toward a comprehensive combined biomarkers strategy. In 
this cross-sectional study, the authors measured soluble CSF 
α-syn in PD patients without dementia and found that reduced 
CSF α-syn levels correlated with reduced fMRI sensorimo-
tor connectivity. Indeed, the current challenge as well as the 
future perspective of development of biomarkers in PD is to 
find the best combination of biomarkers to track the disease 
progression since the prodromal stages.
In this context, genetics as well as the possibility to 
share data through consortia will accelerate the pace of PD 
biomarker research.40,141
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